| Univariable analysis | Multivariable analysis | ||||
---|---|---|---|---|---|---|
Variable | HR | 95% CI | P | HR | 95% CI | P |
Age (y) | ||||||
 < 60 vs ≤ 60 | 0.959 | 0.684 to 1.344 | 0.807 |  |  |  |
Sex | ||||||
 Female vs male | 1.014 | 0.733to 1.402 | 0.935 |  |  |  |
Smoking status | ||||||
 Never vs current/former | 1.136 | 0.786 to 1.643 | 0.497 |  |  |  |
EGFR mutation | ||||||
 Exon 19 | 0.721 | 0.520 to 1.000 | 0.050 | 0.800 | 0.495 to 1.292 | 0.362 |
 Exon 21 | 1.252 | 0.914 to 1.715 | 0.161 | 1.104 | 0.693 to 1.104 | 0.678 |
First-line TKI therapy | ||||||
 Yes v no | 1.480 | 1.077 to 2.032 | 0.016 | 1.358 | 0.985 to 1.872 | 0.061 |
Lung-molGPA | Â | Â | Â | Â | Â | Â |
 1–2 v 2.5–4 | 0.513 | 0.374 to 0.703 |  < 0.001 | 0.606 | 0.433 to 0.849 | 0.004 |
Radiotherapy strategies | ||||||
 WBRT | 1.835 | 1.326 to 2.539 |  < 0.001 | 1.529 | 1.084 to 2.157 | 0.016 |
 Local radiotherapy | 0.456 | 0.299 to 0.694 |  < 0.001 | 0.530 | 0.340 to 0.827 | 0.005 |
 WBRT + Boost | 0.623 | 0.434 to 0.894 | 0.010 | 0.744 | 0.509 to 1.087 | 0.126 |
Brain metastatic time | ||||||
 Initial treatment vs In the course of treatment | 1.083 | 0.923 to 1.271 | 0.329 |  |  |  |